Liyan Chen

1.2k citations
33 papers · 851 indexed · h-index 18
Topics
Pancreatic and Hepatic Oncology Research (3 papers)Cancer-related molecular mechanisms research (3 papers)Cancer-related Molecular Pathways (3 papers)

In The Last Decade

Liyan Chen

32 papers receiving 847 citations

Peers

Liyan Chen
Comparison fields: 5 of 93
  • Molecular Biology 581
  • Cancer Research 164
  • Oncology 160
  • Cell Biology 122
  • Pulmonary and Respiratory Medicine 113
Replace Samriddhi Shukla with:
Samriddhi Shukla India
Donghwa Kim South Korea
Riccardo Di Fiore Italy
Lieqi Liu Canada
Peng Zou China
Ignacio Dolado Spain
Manuela Gridling Austria
Moon‐Taek Park South Korea
Joanna Zawacka‐Pankau Sweden
Liyan Chen relative to Samriddhi Shukla India Samriddhi Shukla's profile →
Citations per field
00.5×3.6×
Samriddhi Shukla · 1×
Citations per year

Countries citing papers authored by Liyan Chen

Since Specialization
Citations

This map shows the geographic impact of Liyan Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liyan Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liyan Chen more than expected).

Fields of papers citing papers by Liyan Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liyan Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liyan Chen. The network helps show where Liyan Chen may publish in the future.

Co-authorship network of co-authors of Liyan Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Liyan Chen. A scholar is included among the top collaborators of Liyan Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liyan Chen. Liyan Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 8
3 23
4 37
5
[G6PC knockdown blocks AKT/mTOR pathway to inhibit proliferation, invasion and migration of cervical cancer HeLa cells].
0
6 42
7 94
8 15
9 30
10 15
11 15
12 21
13 42
14 17
15 31
16 44
17 147
18 9
19 49
20 8

About Liyan Chen

Liyan Chen is a scholar working on Toxicology, Hepatology and Cancer Research, having authored 33 papers that have together received 851 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (3 papers), Cancer-related molecular mechanisms research (3 papers) and Cancer-related Molecular Pathways (3 papers). The work is most often cited by research in Toxicology (74 citations), Cancer Research (164 citations) and Molecular Biology (581 citations). Liyan Chen has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Zhenhua Lin, Jie Sun, Junjie Piao, Tiefeng Jin, Ming Xu, Xuelian Cui, Shuangping Liu, Qunying Wu, Yang� Yang and Yan Zhang. Their work appears in journals such as PLoS ONE, Oncogene and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026